Patent Grant
11433107
This document relates to the field of bacterial compositions. For example, this document provides bacterial compositions having combinations of different bacterial strains formulated in a manner to maintain the stability of the bacteria.
Consuming particular microorganisms in the form of a probiotic formulation can provide health benefits to mammals. There are hundreds of different bacterial strains within a human's digestive system. It is believed that some of these different bacteria help maintain a healthy digestive tract and help digest food.
Unfortunately, probiotic strains are extremely sensitive, and some strains may not be able to survive commercial production, storage, or gastrointestinal transit after consumption where they are exposed to heat, moisture, bile, low pH, and digestive enzymes. As a result, an undesirable reduction in the probiotic strain count occurs before the bacteria reach the intestine.
This document provides bacterial compositions. For example, this document provides bacterial compositions having a combination of different bacterial strains formulated in a manner to maintain the stability of the bacteria. For example, the methods and materials provided herein can be used to deliver an effective and live dose of probiotics, to protect the probiotics during shelf life storage, and to achieve gastrointestinal bioavailability.
As described herein, a single bacterial composition (e.g., a capsule or tablet or sachet) can be formulated to include at least seven different bacterial strains, a form of silica (e.g., silica powder), fructooligosacchride, magnesium stearate, and a low moisture filler (e.g., a microcrystalline cellulose such as MCC 112) to provide a final composition with a water activity (Aw) less than 0.3 in a manner that helps maintain the stability of the bacteria within the composition and in a manner that delivers the bacteria to the intestines following oral administration. For example, at least about 1×109 colony forming units (CFUs) of each of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum can be formulated with silica, fructooligosacchride, magnesium stearate, and a filler with a lower water content to form compositions with an Aw less than 0.3 that maintain the viability of at least about 80 percent of the bacteria for at least about 12 months, at least about 18 months, or at least about 24 months, under standard storage conditions (e.g., room temperature under normal humidity).
As used herein, the term “about” when used to refer to weight % in a composition means±10% of the reported weight %. As used herein, the term “about” when used to refer to measured characteristics of the composition means±20% of the reported value.
The bacterial compositions provided herein can be coated with a coating agent and/or encapsulated to minimize or prevent moisture adsorption and to minimize water activity of the final blend.
In general, one aspect of this document features a bacterial composition comprising the bacteria Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum, wherein the bacterial composition releases the Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum within an intestine of a mammal following oral administration to the mammal, and wherein the composition has a water activity less than 0.3. For every gram of the composition, the composition can comprise between about 4×109 colony forming units and about 50×109 colony forming units of Lactobacillus acidophilus. For every gram of the composition, the composition can comprise between about 5×109 colony forming units and about 60×109 colony forming units of Lactobacillus plantarum. For every gram of the composition, the composition can comprise between about 4×109 colony forming units and about 50×109 colony forming units of Lactobacillus casei. For every gram of the composition, the composition can comprise between about 4×109 colony forming units and about 50×109 colony forming units of Lactobacillus rhamnosus. For every gram of the composition, the composition can comprise between about 2×109 colony forming units and about 40×109 colony forming units of Bifidobacterium longum. For every gram of the composition, the composition can comprise between about 4×109 colony forming units and about 50×109 colony forming units of Bifidobacterium lactis. For every gram of the composition, the composition can comprise between about 2×109 colony forming units and about 40×109 colony forming units of Bifidobacterium bifidum. The composition can comprise fructooligosaccharides. For every gram of the composition, the composition can comprise between about 0.5 mg and about 50 mg of fructooligosaccharides. The composition can comprise silicon dioxide. For every gram of the composition, the composition can comprise between about 5 mg and about 20 mg of silicon dioxide. The composition can comprise magnesium stearate. For every gram of the composition, the composition can comprise between about 10 mg and about 20 mg of magnesium stearate. For every gram of the composition, the composition can comprise more than 8×109 CFUs of bacteria. For every gram of the composition, the composition can comprise more than 10×109 CFUs of bacteria. For every gram of the composition, the composition can comprise more than 15×109 CFUs of bacteria. For every gram of the composition, more than 10×109 CFUs of bacteria of the composition remain viable after about 12 months of storage at room temperature and environmental humidity. For every gram of the composition, more than 10×109 CFUs of bacteria of the composition remain viable after about 12 months of storage at room temperature and environmental humidity. The Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum can be lyophilized. The mammal can be a human. The bacterial composition can comprises a coating that prevents release of the Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum until the composition reaches an intestine of the mammal following oral administration to the mammal. The bacterial composition can comprise a capsule housing the Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum. The composition can comprise a microcrystalline cellulose.
In another aspect, this document features a method for making a bacterial composition. The method comprises, or consists essentially of, (a) coating lyophilized bacteria with silicon dioxide to form coated lyophilized bacteria, (b) adding MCC having a water activity of less than 0.2 and fructooligosaccharides to the coated lyophilized bacteria to form a first mixture, (c) adding magnesium stearate and silicon dioxide to the first mixture to form a blend, and (d) encapsulating the blend into a dosage form, thereby forming the bacterial composition. The lyophilized bacteria can be a mixture of lyophilized Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum. For every gram of the composition, the composition can comprise (a) between about 4×109 colony forming units and about 50×109 colony forming units of Lactobacillus acidophilus; (b) between about 5×109 colony forming units and about 60×109 colony forming units of Lactobacillus plantarum; (c) between about 4×109 colony forming units and about 50×109 colony forming units of Lactobacillus casei; (d) between about 4×109 colony forming units and about 50×109 colony forming units of Lactobacillus rhamnosus; (e) between about 2×109 colony forming units and about 40×109 colony forming units of Bifidobacterium longum; (f) between about 4×109 colony forming units and about 50×109 colony forming units of Bifidobacterium lactis; and (g) between about 2×109 colony forming units and about 40×109 colony forming units of Bifidobacterium bifidum. For every gram of the composition, the composition can comprise between about 0.5 mg and about 5.0 mg of fructooligo-saccharides. For every gram of the composition, the composition can comprise between about 5.0 mg and about 20.0 mg of silicon dioxide. For every gram of the composition, the composition can comprise more than 15×109 CFUs of bacteria. For every gram of the composition, more than 10×109 CFUs of bacteria of the composition remain viable after about 12 months of storage at room temperature and environmental humidity. The dosage form can be a capsule.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
This document provides bacterial compositions. For example, this document provides bacterial compositions having a combination of different bacterial strains (e.g., a combination of at least six, seven, eight, nine, or ten different bacterial strains) formulated in a manner to maintain the stability of the bacteria. The bacterial compositions provided herein can be in the form of powders, capsules, pills, tablets, chewing gums, lozenges, candy, or sachets. In some cases, a bacterial composition provided herein can include a coating designed to prevent moisture adsorption and minimize the water activity of the final blend to provide a formulation with good long term stability.
For example, methacrylate coatings, hydroxy propyl methyl cellulose pthalate coatings, cellulose acetate succinate coatings, hydroxy propyl methyl cellulose acetate succinate coatings, polyvinyl acetate pthalate coatings, or cellulose acetate trimellitate sodium alginate coatings can be used to deliver the bacterial contents of a bacterial composition past the stomach. Such coatings can be made and applied as described elsewhere (e.g., U.S. Patent Application Publication No. 2014/370091, Chinese Patent No. CN103976975, and Taiwan Patent No. TW201431561).
In some cases, a bacterial composition provided herein can include any combination of at least six (e.g., at least seven, eight, nine, or ten) different bacterial strains. Examples of different bacterial strains that can be formulated into a bacterial composition provided herein include, without limitation, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium bifidum, Bacillus coagulans, Lactobacillus paracasei, Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus bulgaricus, Bifidobacterium breve, Lactobacillus brevis, Lactococcus lactis and Streptococcus thermophilus. In some cases, a bacterial composition provided herein can include one or more bacterial species such as Saccharomyces boulardii In some cases, the only bacterial strains present within a particular bacterial composition can be Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum, or any combination of six selected from Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum.
Unless otherwise noted, all bacteria amounts in this application are provided on a per gram of total bacterial composition in the composition basis. In some cases, a bacterial composition provided herein can contain at least about 1×109 CFUs of each different bacterial strain included in the bacterial composition. In some cases, a bacterial composition provided herein can contain between about 1×108 and about 1×1011 bacteria of all species (e.g., between about 1×109 and about 4×1010 bacteria of all species). For example, a bacterial composition provided herein can include between about 1×107 CFUs and about 3×109 CFUs of Lactobacillus acidophilus, between about 1×107 CFUs and about 4×109 CFUs of Lactobacillus plantarum, between about 1×107 CFUs and about 3×109 CFUs of Lactobacillus casei, between about 1×107 CFUs and about 3.2×109 CFUs of Lactobacillus rhamnosus, between about 1×107 CFUs and about 1.6×109 CFUs of Bifidobacterium longum, between about 1×107 CFUs and about 3.6×109 CFUs of Bifidobacterium lactis, and between about 1×107 CFUs and about 1.6×109 CFUs of Bifidobacterium bifidum.
Any appropriate method can be used to obtain the bacterial strains to be included within a bacterial composition provided herein. For example, culturing techniques can be used to obtain large amounts of particular bacterial strains. In some cases, the bacterial strains to be included within a bacterial composition provided herein can be obtained commercially. For example, Lactobacillus acidophilus can be obtained commercially from Dupont Inc. (Madison, Wis.; Cat. No. LA-14 200B); Lactobacillus plantarum can be obtained commercially from Dupont Inc. (Madison, Wis.; Cat. No. LP-115 400B); Lactobacillus casei can be obtained commercially from Dupont Inc. (Madison, Wis.; Cat. No. LC-11 300B), Lactobacillus rhamnosus can be obtained commercially from Dupont Inc. (Madison, Wis.; Cat. No. LR-32 200B), Bifidobacterium longum can be obtained commercially from Dupont Inc. (Madison, Wis.; Cat. No. BL-05 100B), Bifidobacterium lactis, can be obtained commercially from Dupont Inc. (Madison, Wis.; Cat. No. BL-04 450B), and Bifidobacterium bifidum can be obtained commercially from Dupont Inc. (Madison, Wis.; Cat. No. BB-06 100B).
A bacterial composition provided herein can include one or more other ingredients. For example, a bacterial composition provided herein can include fructooligosaccharides. In some cases, a bacterial composition provided herein can include between about 0.5 mg and about 50 mg (e.g., between about 1 mg and about 50 mg, between about 5 mg and about 50 mg, between about 10 mg and about 50 mg, between about 0.5 mg and about 25 mg, between about 0.5 mg and about 20 mg, between about 0.5 mg and about 15 mg, between about 0.5 mg and about 10 mg, or between about 5 mg and about 20 mg) of fructooligosaccharides per bacterial composition. For example, a bacterial composition provided herein can contain Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum and between about 5 mg and about 20 mg of fructooligosaccharides.
In some cases, a bacterial composition provided herein can include between about 1 mg and about 50 mg (e.g., between about 1 mg and about 20 mg, between about 2 mg and about 20 mg, or between about 2 mg and about 10 mg) of fructooligosaccharides for every gram of the bacterial composition. For example, a bacterial composition provided herein that weighs 2 grams can contain between about 10 mg and about 100 mg of fructooligosaccharides.
Any appropriate method can be used to obtain fructooligosaccharides that can be included in a bacterial composition provided herein. For example, fructooligosaccharides can be obtained by an inulin degradation process or by a transfructosylation process as described elsewhere (U.S. Patent Application Publication No. 2005/069627). In some cases, fructooligosaccharides can be obtained commercially from Agaviotica Inc. (Monterrey, NL (Mexico); Cat. No. Fructagave PR-95).
In some cases, a bacterial composition provided herein can include a glidant (e.g., silica). Examples of glidants that can be included within a bacterial composition provided herein include, without limitation, silica, stearic acid, calcium stearate, magnesium stearate, sodium stearate, glyceryl behapate (compritol), liquid paraffin, Aerosil® (colloidal silicon dioxide), starch and talc, DL-leucine, and sodium lauryl sulfate. For example, a bacterial composition provided herein can include between about 2.00 mg and about 5.00 mg (e.g., between about 0.005 mg and about 010 mg, between about 0.01 mg and about 0.02 mg, or between about 0.25 mg and about 0.50 mg) of a glidant (e.g., silica) per bacterial composition. For example, a bacterial composition provided herein can contain Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum and between about 0.005 mg and about 0.02 mg of silica.
In some cases, a bacterial composition provided herein can include between about 2.0 mg and about 5.0 mg of a glidant (e.g., silica) for every gram of the bacterial composition. For example, a bacterial composition provided herein that weighs 2 grams can contain between about 4.0 mg and about 10.0 mg of a glidant (e.g., silica).
Any appropriate method can be used to obtain of a glidant (e.g., silica) that can be included in a bacterial composition provided herein. For example, silica can be obtained as described elsewhere (U.S. Patent Application Publication No. 2006/153764). In some cases, silica can be obtained commercially from Grace Davison Inc. (Baltimore, Md.; Cat. No. Syloid 244).
In some cases, a bacterial composition provided herein can include a filler having an Aw of less than 0.2. Examples of such fillers include, without limitation, microcrystalline cellulose (MCC 112), rice maltodextrin, lactose anhydrous, mannitol, microcrystalline cellulose (MCC 302), microcrystalline cellulose (MCC 200 LM), microcrystalline cellulose (MCC 101), starch, xylitol, sorbitol, hydroxyl propyl cellulose, a gelatin, polyvinyl pyrrolidone, and dibasic calcium phosphate. In some cases, a bacterial composition provided herein can include between about 300 mg and about 700 mg of a filler having an Aw of less than 0.2 (e.g., MCC 112) per bacterial composition. For example, a bacterial composition provided herein can contain Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum and between about 300 mg and about 700 mg of a filler having an Aw of less than 0.2 (e.g., MCC 112). In some cases, a bacterial composition provided herein can include between about 300 mg and about 700 mg of a filler having an Aw of less than 0.2 (e.g., MCC 112) for every gram of the bacterial composition. For example, a bacterial composition provided herein that weighs 2 grams can contain between about 600 mg and about 1400 mg of a filler having an Aw of less than 0.2 (e.g., MCC 112). As a result, the final composition can have an Aw of less than 0.3.
Any appropriate method can be used to obtain a filler having an Aw of less than 0.2 for use in the bacterial compositions provided herein. For example, a filler having an Aw of less than 0.2 can be obtained as described elsewhere (U.S. Patent Application Publication No. US20140322282, published Oct. 30, 2014). In some cases, a filler having an Aw of less than 0.2 can be obtained commercially from Mingtai chemical Co Ltd., Taiwan, Cat. No. M112 D.
In some cases, a bacterial composition provided herein can include magnesium stearate. For example, a bacterial composition provided herein can include between about 10 mg and about 20 mg of magnesium stearate per bacterial composition. For example, a bacterial composition provided herein can contain Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum and between about 10 mg and about 20 mg of magnesium stearate.
In some cases, a bacterial composition provided herein can include between about 10 mg and about 20 mg of magnesium stearate for every gram of the bacterial composition. For example, a bacterial composition provided herein that weighs 2 grams can contain between about 20 mg and about 40 mg of magnesium stearate.
Any appropriate method can be used to obtain magnesium stearate that can be included in a bacterial composition provided herein. For example, magnesium stearate can be obtained as described elsewhere (e.g., Chinese Patent No. CN103880645, dated Jun. 25, 2014; Chinese Patent No. CN103524324, dated Jan. 22, 2014, and Chinese Patent No. CN10319361, dated Jul. 10, 2013). In some cases, magnesium stearate can be obtained commercially from Peter Greven Asia, Malaysia; Cat. No. Palmstar MGST 200. A bacterial composition provided herein (e.g., a capsule or tablet) can be formulated to have a particular dose. For example, a bacterial composition provided herein can be in the form of a capsule or tablet with a total weight that is between about 150 mg and about 800 mg (e.g., between about 200 mg and about 800 mg, between about 300 mg and about 800 mg, between about 350 mg and about 800 mg, between about 150 mg and about 700 mg, between about 150 mg and about 650 mg, or between about 350 mg and about 700 mg).
As described herein, a single bacterial composition (e.g., a capsule or tablet) can be formulated to include at least six different bacterial strains and a filler having an Aw less than 0.2 (e.g., MCC 112) in a manner that helps maintain the stability of the bacteria within the composition. In some cases, a single bacterial composition provided herein can be coated with at coating or placed into a capsule having the ability to deliver the contents to the intestines of a mammal following oral administration. For example, a bacterial composition provided herein can be designed to release its contents when the composition reaches a location of the intestines having a pH above about 6.8. In some cases, a bacterial composition that includes at least seven different bacterial strains and a filler having an Aw less than 0.2 (e.g., MCC 112) can include fructooligosaccharides, magnesium stearate, and/or silica. In some cases, the bacterial strains of a bacterial composition provided herein can be lyophilized to form a dried powder containing viable bacteria. In some cases, a single bacterial composition (e.g., a capsule or tablet or sachet) can be formulated to include at least seven different lyophilized bacterial strains, a filler having an Aw less than 0.2 (e.g., MCC 112), fructooligosaccharides, magnesium stearate, and silica.
In some cases, a bacterial composition provided herein can maintain the viability of at least about 80 percent (e.g. at least about 90, 95, or 99 percent) of the bacteria for at least 12 months (e.g., at least 40, 50, 60, 70, 80, or 90 days or at least 3, 6, 9, or 12 months) under standard storage conditions (e.g., room temperature under normal humidity). In some cases, a bacterial composition provided herein can maintain the viability of at least about 80 percent of the bacteria for at least 18 months or for at least 24 months.
The bacterial composition provided herein can be administered to a mammal (e.g., a human). In some cases, a human can be instructed to self-administer a number (e.g., one, two, three, four, five, or more) bacterial compositions provided herein (e.g., capsules or tablets or sachets) per unit time (e.g., per day, per week, or per month). For example, a human can be instructed to self-administer one or two bacterial compositions provided herein (e.g., a capsule of Example 1) per day.
The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
Two bacterial compositions were produced (Prototype trial 1 and Prototype trial 2) as follows. The final formulations were stored in various bottles as described below:
(i) MCC 101 and MCC 112 were used as diluent in prototype trials.
(ii) PET bottle, HDPE bottle, and sealed Aluminum foil packet were used in storing the final capsule.
Prototype trial 1:
Lactobacillus acidophilus
Bifidobacterium lactis
Lactobacillus acidophilus
Bifidobacterium lactis
Lactobacillus acidophilus
Bifidobacterium lactis
Once produced, the two bacterial compositions were tested for stability (Table 1).
These results demonstrate that, using microcrystalline cellulose in bacterial compositions having at least two strains, MCC 112 improved stability over MCC 101 and that using a High Density Polyethylene (HDPE) bottle or Aluminum foil packet improved stability over using a PET bottle.
A bacterial composition was produced as follows.
Lactobacillus acidophilus
Lactobacillus plantarum
Lactobacillus casei
Lactobacillus rhamnosus
Bifidobacterium longum
Bifidobacterium lactis
Bifidobacterium bifidum
400 mg of the above blend was filled into a single DR capsule. The potency of the 400 mg of blend was 20 billion CFUs/capsule.
Once produced, the bacterial composition was tested for stability (Table 2).
These results confirm that using microcrystalline cellulose MCC 112 and a High Density Polyethylene (HDPE) bottle maintained stability in a bacterial composition having seven strains of bacteria.
A bacterial composition was prepared as follows (Table 3). Briefly, lyophilized bacteria of varying CFUs of each of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, and Bifidobacterium bifidum and silicon dioxide (silica; 2 mg) were blended for two minutes to coat the dried bacteria uniformly. The silica can adsorb moisture, keeping the lyophilized bacteria dry with minimal water activity and improving the stability of final formulation. MCC 112 (grade of microcrystalline cellulose with Aw of less than 0.2 (700 mg), and fructooligosaccharides (50 mg) were then added, and the mixture was blended for an additional 20 minutes. After blending, additional silica (3 mg) as a glidant and magnesium stearate (15 mg) as lubricant, were added, and the mixture was blended for another three minutes. The final mixture was inserted into capsules (e.g., DR capsules). DR capsules are vegetarian capsules made with a hypromellose (HPMC) formulation that can help protect sensitive ingredients from the low pH environment of the stomach. By protecting against early disintegration, disintegration generally starts approximately 45 minutes later than a typical immediate release capsule of about 5 minutes, and the ingredients are released in the intestine in alkaline pH.
Lactobacillus
acidophilus
Lactobacillus
plantarum
Lactobacillus
casei
Lactobacillus
rhamnosus
Bifidobacterium
longum
Bifidobacterium
lactis
Bifidobacterium
bifidum
74%
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
This application is a continuation of U.S. application Ser. No. 14/986,854, filed on Jan. 4, 2016, which claims the benefit of U.S. Provisional Application No. 62/099,410 filed on Jan. 2, 2015, the contents of these aforementioned applications are hereby incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4897224 | Kondo et al. | Jan 1990 | A |
| 5502045 | Miettinen et al. | Mar 1996 | A |
| 6008027 | Langner | Dec 1999 | A |
| 6087353 | Stewart et al. | Jul 2000 | A |
| 6333047 | Katagihara et al. | Dec 2001 | B1 |
| 6441206 | Mikkonen et al. | Aug 2002 | B1 |
| 6596306 | Ho et al. | Jul 2003 | B1 |
| 6713096 | Cho | Mar 2004 | B2 |
| 6818233 | Perkes | Nov 2004 | B2 |
| 6964969 | McCleary | Nov 2005 | B2 |
| 7138149 | Cho | Nov 2006 | B2 |
| 7229651 | Perkes | Jun 2007 | B2 |
| 7923041 | Stock et al. | Apr 2011 | B2 |
| 8071610 | Reynolds | Dec 2011 | B2 |
| 8168170 | Matt | May 2012 | B2 |
| 8273393 | Rabovsky et al. | Sep 2012 | B2 |
| 8491939 | Rabovsky et al. | Jul 2013 | B2 |
| 8697158 | Rabovsky et al. | Apr 2014 | B2 |
| 8722035 | Porubcan | May 2014 | B2 |
| 8747915 | Giampapa | Jun 2014 | B1 |
| 9034399 | Rabovsky et al. | May 2015 | B2 |
| 9179693 | Romero et al. | Nov 2015 | B2 |
| 9210945 | Horgan et al. | Dec 2015 | B2 |
| 9259448 | Derrieu | Feb 2016 | B2 |
| 10576112 | Nayak | Mar 2020 | B2 |
| 11207388 | Rabovsky et al. | Dec 2021 | B2 |
| 20040001817 | Giampapa | Jan 2004 | A1 |
| 20040175389 | Porubcan | Sep 2004 | A1 |
| 20040228931 | Chokshi et al. | Nov 2004 | A1 |
| 20050032757 | Cho | Feb 2005 | A1 |
| 20050069627 | Mysore et al. | Mar 2005 | A1 |
| 20050244510 | Smith | Nov 2005 | A1 |
| 20060153764 | Schumacher et al. | Jul 2006 | A1 |
| 20060193842 | Porubcan | Aug 2006 | A1 |
| 20070099986 | Ishichi | May 2007 | A1 |
| 20070154575 | Shimoda et al. | Jul 2007 | A1 |
| 20080181937 | Fotuhi | Jul 2008 | A1 |
| 20090175936 | Rohr | Jul 2009 | A1 |
| 20090175968 | Ivie et al. | Jul 2009 | A1 |
| 20090181974 | Bourgeade et al. | Jul 2009 | A1 |
| 20090263492 | Cashman et al. | Oct 2009 | A1 |
| 20100166721 | Masri | Jul 2010 | A1 |
| 20110008493 | Zorea | Jan 2011 | A1 |
| 20110027418 | Horgan et al. | Feb 2011 | A1 |
| 20110038848 | Rabovsky et al. | Feb 2011 | A1 |
| 20110064720 | Amato | Mar 2011 | A1 |
| 20110189132 | Garner et al. | Aug 2011 | A1 |
| 20110206721 | Nair | Aug 2011 | A1 |
| 20120009278 | Perry | Jan 2012 | A1 |
| 20120034324 | Dubey | Feb 2012 | A1 |
| 20120064051 | Mercenier et al. | Mar 2012 | A1 |
| 20130216521 | Culver et al. | Aug 2013 | A1 |
| 20140037582 | Romero et al. | Feb 2014 | A1 |
| 20140322282 | Tuason et al. | Oct 2014 | A1 |
| 20140370091 | Kikuchi et al. | Dec 2014 | A1 |
| 20150166466 | Kramer et al. | Jun 2015 | A1 |
| 20160193261 | Nayak | Jul 2016 | A1 |
| 20160193273 | Rabovsky et al. | Jul 2016 | A1 |
| 20160193306 | Rabovsky et al. | Jul 2016 | A1 |
| 20190167751 | Rabovsky | Jun 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 1254256 | May 2000 | CN |
| 1875094 | Dec 2006 | CN |
| 103193614 | Jul 2013 | CN |
| 103524324 | Jan 2014 | CN |
| 103664667 | Mar 2014 | CN |
| 103880645 | Jun 2014 | CN |
| 103951618 | Jul 2014 | CN |
| 103976975 | Aug 2014 | CN |
| 2520177 | May 2017 | EP |
| 2013-530196 | Jul 2013 | JP |
| 201431561 | Aug 2014 | TW |
| WO 1999007400 | Feb 1999 | WO |
| WO 03026687 | Apr 2003 | WO |
| WO 2004022031 | Mar 2004 | WO |
| WO 2006026713 | Mar 2006 | WO |
| WO 2006097043 | Sep 2006 | WO |
| WO 2007140621 | Dec 2007 | WO |
| WO 2010006173 | Jan 2010 | WO |
| WO 2011004375 | Jan 2011 | WO |
| WO 2011019867 | Feb 2011 | WO |
| WO 2011019875 | Feb 2011 | WO |
| WO 2012123770 | Sep 2012 | WO |
| WO 201311100 | Aug 2013 | WO |
| WO 2014025905 | Feb 2014 | WO |
| WO 2014070014 | May 2014 | WO |
| WO 2014151329 | Sep 2014 | WO |
| WO 2014152236 | Sep 2014 | WO |
| WO 2014195741 | Dec 2014 | WO |
| WO 2015017625 | Feb 2015 | WO |
| WO 2015091365 | Jun 2015 | WO |
| Entry |
|---|
| Bryan, et al., J. Nutr., 132:1345. (Year: 2002). |
| Di Meo, et al., J. Exp. Clin. Cancer Res., 38:360. (Year: 2019). |
| Lee, et al., Curr. Neuropharmacol., 11:338. (Year: 2013). |
| Memory Pro 2011 product listing, retrieved from the Wayback Machine, Internet Archive, (https://web.archive.org/web/20111025131756/http://pureencapsulations.com/itemdy00.asp?T1=MEP1). (Year: 2011). |
| Memory Pro, Dietary Supplement, Manufacturer: Pure Encapsulations®, Available on Amazon.com, https://vwvw.amazon.com/Pure-Encapsulations-Supplement-Broad-Spectrum-Capsules/dp/B01N9VLP1Z?ref_=ast sto_dp#customerReviews. (Year: 2008). |
| Xu, et al., Acta Pharmacologice Sinica, 16:391. (Year: 1995). |
| U.S. Appl. No. 62/099,407, filed Jan. 2, 2015, Rabovsky et al. |
| Bassenge et al., “Dietary supplement with vitamin C prevents nitrate tolerance,” J Clin Invest., 102(1):67-71, Jul. 1, 1998. |
| Bobko et al., “Trityl-based EPR probe with enhanced sensitivity to oxygen,” Free Radic Biol Med., 47(5):654-658, Epub Jun. 10, 2009. |
| Dikalov et al., “ESR techniques for the detection of nitric oxide in vivo and in tissues,” Methods Enzymol., 396:597-610, 2005. |
| Extended European Search Report in Application No. 16732905.1, dated Jun. 14, 2018, 9 pages. |
| Falbe, Ed., “Emulsions (HLB Values),” Surfactants in Consumer Products, 4.2.4 pp. 149-153, 1989. |
| Feuerstein et al., “Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha,” Cerebrovasc Brain Metab Rev., 6(4):341-360, Winter 1994. |
| Fink et al., “A new approach for extracellular spin trapping of nitroglycerin-induced superoxide radicals both in vitro and in vivo,” Free Radic Biol Med., 28(1):121-128, Jan. 1, 2000. |
| International Preliminary Report on Patentability for International Application No. PCT/US2016/012060, dated Jul. 13, 2017, 8 pages. |
| International Preliminary Report on Patentability for International Application No. PCT/US2016/012063, dated Jul. 13, 2017, 7 pages. |
| International Preliminary Report on Patentability for International Application No. PCT/US2016/012091, dated Jul. 13, 2017, 7 pages. |
| International Search Report and Written Opinion for PCT/US2016/012060, dated May 2, 2016, 13 pages. |
| International Search Report and Written Opinion for PCT/US2016/012091, dated Mar. 17, 2016, 12 pages. |
| Komarov et al., “Electron paramagnetic resonance monitoring of ischemia-induced myocardial oxygen depletion and acidosis in isolated rat hearts using soluble paramagnetic probes,” Magn Reson Med., 68(2):649-655, Epub Dec. 12, 2011. |
| Mrakic-Sposta et al., “Assessment of a standardized ROS production profile in humans by electron paramagnetic resonance,” Oxid Med Cell Longev., vol. 2012 Article ID 973927, 10 pages, 2012. |
| Partial Supplementary European Search Report in Application No. 16732909.3, dated Jul. 25, 2018, 12 pages. |
| Pisaneschi et al., “Compensatory feto-placental upregulation of the nitric oxide system during fetal growth restriction,” PLoS One, 7(9):e45294, Epub Sep. 27, 2012. |
| Purest Colloids, Inc., “Theralac Probiotic,” Purest Colloids [online] copyright 2014 [retrieved on Dec. 18, 2014]. Retrieved from the Internet: <URL:www.purestcolloids.com/inside-theralac.php>, 2 pages. |
| Wikipedia, “Acetylcarnitine,” Wikipedia.org [online] last modified Sep. 20, 2014. Retrieved from the Internet: <URL:http://en.wikipedia.org/wiki/Acetylcarnitine>. Retrieved on Nov. 19, 2014, 4 pages. |
| Wikipedia, “Curcumin,” Wikipedia.org [online] last modified Nov. 7, 2014. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/Curcumin>, retrieved on Nov. 20, 2014, 6 pages. |
| Wikipedia, “Huperzine A,” Wikipedia.org [online], last modified Nov. 10, 2014. Retrieved from the Internet: <http://en.wikipedia.org/wiki/Huperzine_A>, 4 pages. |
| Wong et al., “Treatment of non-alcoholic steatohepatitis with probiotics. A proof-of-concept study,” Annals Hepatol., 12(2):256-262, Mar. 1, 2013. |
| Wong et al., “Treatment of non-alcoholic steatohepatitis with probiotics. A proof-of-concept study,” Annals of hepatology., 12(2):256-262, Mar. 1, 2013. |
| Uabundit et al., Journal of Ethnopharmacology, 127:26, 2010. |
| Number | Date | Country | |
|---|---|---|---|
| 20200197454 A1 | Jun 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62099410 | Jan 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14986854 | Jan 2016 | US |
| Child | 16804458 | US |
